RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Amplia Therapeutics Stock

Amplia Therapeutics Stocks 2024

Amplia Therapeutics Stocks

199.62 M

Ticker

ATX.AX

ISIN

AU0000023822

WKN

A2N5RL

In 2024, Amplia Therapeutics had 199.62 M outstanding stocks, a 0.02% change from the 199.58 M stocks in the previous year.

The Amplia Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined AUD)
2024199.62
2023199.58
2022149.76
202198.46
202052.96
201943.43
201824.65
201723.24
201620.04
201517.46
201411.94
20139.63
201218.49

Amplia Therapeutics shares outstanding

The number of shares was Amplia Therapeutics in 2023 — This indicates how many shares 199.583 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amplia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amplia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amplia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amplia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amplia Therapeutics Aktienanalyse

What does Amplia Therapeutics do?

Amplia Therapeutics Ltd was originally founded in 2012 and is based in Sydney, Australia. The company focuses on the development of novel therapies for cancer and other serious diseases. Amplia's main focus is on the development of peptide-based therapeutics, which are polypeptides derived from naturally occurring proteins. The company also places special emphasis on non-coding RNA (ncRNA) research and is working on the discovery, development, and commercialization of drugs that specifically target ncRNA. Amplia already holds various patents and approvals in this field. Amplia's core business is the research and development of drugs for cancer. The company collaborates with academic research groups and institutions worldwide and works closely with manufacturers of synthetic peptides to ensure high quality and efficacy in drug production. Amplia has developed various drug platforms to support its research activities. One of these platforms is the peptide library, which contains a large collection of synthetic peptides that can be used against different types of cancer. Another platform is ncRNA-based therapeutics, which exert their effects by inhibiting ncRNA molecules. Currently, Amplia Therapeutics has several drugs in various stages of clinical development. One example is AMP945, a peptide designed as a potential medication for triple-negative breast cancer. The drug targets a protein receptor found on the surface of cancer cells and has shown promising results in inhibiting tumor growth in animal models. Another example is ATX101, an ncRNA inhibitor also being developed as a potential medication for cancer. The inhibitor targets a specific form of ncRNA molecule that is overproduced in various types of cancer. In animal models, the drug has shown promising results in preventing tumor progression. Overall, Amplia Therapeutics Ltd aims to develop drugs that can significantly improve the lives of patients. The company strives to set new standards in cancer therapy and continuously works to improve its technology platforms and expand its product pipeline. Amplia Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Amplia Therapeutics's Shares Outstanding

Amplia Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Amplia Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Amplia Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Amplia Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Amplia Therapeutics stock

How many stocks are there of Amplia Therapeutics?

The current number of stocks of Amplia Therapeutics is 199.62 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Amplia Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Amplia Therapeutics evolved in recent years?

The number of shares of Amplia Therapeutics has increased by 0.02% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Amplia Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Amplia Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Amplia Therapeutics pay?

Over the past 12 months, Amplia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amplia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Amplia Therapeutics?

The current dividend yield of Amplia Therapeutics is .

When does Amplia Therapeutics pay dividends?

Amplia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amplia Therapeutics?

Amplia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Amplia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amplia Therapeutics located?

Amplia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amplia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amplia Therapeutics from 10/2/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Amplia Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Amplia Therapeutics in the year 2023?

In the year 2023, Amplia Therapeutics distributed 0 AUD as dividends.

In which currency does Amplia Therapeutics pay out the dividend?

The dividends of Amplia Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Amplia Therapeutics

Our stock analysis for Amplia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amplia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.